Gatti, Milo http://orcid.org/0000-0003-3018-3779
De Ponti, Fabrizio http://orcid.org/0000-0002-0367-9595
Pea, Federico http://orcid.org/0000-0002-6966-7167
Funding for this research was provided by:
Alma Mater Studiorum - Università di Bologna
Article History
Accepted: 26 March 2021
First Online: 18 April 2021
Declarations
:
: Open access funding provided by Alma Mater Studiorum - Università di Bologna within the CRUI-CARE Agreement. No funding was used to assist with the preparation of this review.
: Federico Pea participated in the speaker bureau for Angelini, Basilea Pharmaceutica Gilead, Hikma, Merck Sharp and Dohme, Nordic Pharma, Pfizer and Sanofi Aventis, and in an advisory board for Angelini, Basilea Pharmaceutica, Correvio, Gilead, Merck Sharp and Dohme, Nordic Pharma, Novartis, Pfizer and Thermo–Fisher. Milo Gatti and Fabrizio De Ponti have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: MG and FP made substantial contributions to the conception of the manuscript. MG was involved in drafting the manuscript. FDP and FP made substantial contributions in critically revising the manuscript for important intellectual content. All the authors approved the final version of the manuscript.